CYRAMZA (Ramucirumab) is a human IgG1 monoclonal antibody that has been approved by the FDA for the treatment of some types of cancer. CYRAMZA specifically binds to the extracellular domain of the human vascular endothelial growth factor receptor 2 (VEGFR2), which is important for promoting the growth and spread of cancer cells. As a result, it can be used to help reduce tumor size, prevent the spread of cancer, and in some cases, prolong survival.
Administered as a subcutaneous (underneath the skin) injection
CYRAMZA is administered as a subcutaneous (underneath the skin) injection, usually as a one-time dose. The injection is typically given twice per cycle (every six to eight weeks) for up to eight cycles (32 doses). Doses may need to be adjusted based on the patient’s response to the treatment. The dose and related costs can vary depending on a patient’s tumor type and progression, as well as the justification for treatment, the schedule of the injections, and the size of the area being treated.
The retail price for each 3-mL vial of CYRAMZA is $15,610. This cost is based on an average selling price that is calculated by the manufacturer and may vary depending on the pharmacy a patient purchases their medication from. In addition to this cost, there may also be extra costs associated with administering the injection, lab tests, and professional fees. Some insurance companies may also charge a premium for their coverage. Unfortunately, due to these other variables, it is difficult to provide an accurate estimate of how much an individual would pay for treatment. Generally, the out-of-pocket costs for those with insurance are typically lower than for those without insurance.
Unable to afford the cost of the treatment
For those unable to afford the cost of the treatment, various assistance programs are available. There are various private and government-funded programs designed to help patients cover the cost of their medication and other associated expenses. Patients can also take advantage of manufacturer co-pay assistance programs and patient assistance programs. These programs are available to those who meet income and insurance requirements and can provide relief to those who need it the most.
CYRAMZA is a promising anti-cancer therapy that can help reduce tumor size, prevent the spread of cancer, and extend survival in some patients. Though the retail cost for each vial is high, there are various assistance programs available to help cover the cost of their medication and related expenses for those who cannot afford it.
Monoclonal antibody drug
Ramucirumab is a monoclonal antibody drug used primarily in the treatment of certain types of cancer, such as Non-Small Cell Lung Cancer (NSCLC) and gastric cancer. It works by blocking a protein called VEGF-R2, which plays an important role in the growth and spread of cancer cells. Ramucirumab has been shown to be effective in treating advanced cancer and has been approved for use by the United States Food and Drug Administration (FDA).
Since it was approved by the FDA in 2014, the drug has been made available to many cancer patients. Currently, it is distributed through specialty pharmacies, mail-order pharmacies, and physicians’ offices. The drug is administered intravenously over an approximate one-hour timeframe and is usually given every two weeks.
The average cost of Ramucirumab
The average cost of Ramucirumab Injection is approximately $12,100 for an annual course of treatment. This cost can vary, depending on the prescription plan, drug manufacturer, and the specific medication being used. Moreover, insurance coverage can also greatly influence the cost of Ramucirumab; some plans may provide coverage, while others may not.
Ramucirumab 500mg Injection is a concentration of the drug that is given in 500mg dosages. According to the package inserts, it is administered as a single intravenous infusion over approximately 30 minutes, during every cycle of chemotherapy. The cost of Ramucirumab 500mg Injection is not publicly available but is likely to be higher than the cost of a lower concentration of the drug, due to the higher dosage.
